News & Media

Nobel Laureate Michael Levitt Joins Longevity Science Foundation

November 18, 2021 – The Longevity Science Foundation — dedicated to advancing the healthy human lifespan to more than 120 years — announced today that Nobel Prize-winning chemist Michael Levitt, FRS has joined its Visionary Board. The Board provides scientific strategy advice and direction to the Foundation, which has committed to distributing more than $1 billion over the next 10 years to research, institutions and projects advancing healthy longevity.

"We are extremely proud to have Prof. Levitt joining as our esteemed advisor,” Visionary Board Chairman Evelyne Yehudit Bischof said. “He is an exquisite example of an innovator and pioneer, having been on the cutting edge of revolutionary science, such as computational structural biology, AI-based modelling. His ongoing ground-breaking research, passion and exquisite skill to identify the most promising pursuits to advance science and medicine, will be detrimental in the review of LSF grant laureates.”

The focus of the Foundation is to support projects in four major areas of longevity medicine: therapeutics, predictive diagnostics, personalised medicine, and the application of artificial intelligence.

Prof. Levitt won the 2013 Nobel Prize for Chemistry with Marin Karplus and Arieh Warshel “for the development of multiscale models for complex chemical systems.”

“This is a very exciting time in human development and the field of longevity research,” Levitt said. “We have the opportunity to advance the evolution of mankind and I look forward to reviewing the work that is being done toward this goal and collaborating with my fellow Visionary Board members.”

Prof. Levitt is currently a professor of structural biology at Stanford University in Palo Alto, California. He is a Member of the European Molecular Biology Organisation, a Fellow of the Royal Society and a member of the National Academy of Sciences. He was elected an ISCB Fellow by the International Society for Computational Biology in 2015.

He joins the Visionary Board which includes leading longevity scientists, researchers, and practising clinicians Evelyne Bischof, Andrea B. Maier, Eric Verdin, Matt Kaeberlein, and Alex Zhavoronkov.